Tandem Diabetes Care Stock News

Tandem Diabetes Care has steadily improved its company revenue in each of the last four years.

Don't be too quick to jump on the Shiba Inu bandwagon.

Tandem Diabetes Care Inc (NASDAQ: TNDM ) reported Q4 sales reached $209.9 million , +25% Y/Y, beating the consensus of $199.12 million. The Company posted EPS of $0.16, down from $0.22 a year ago, and missed the Wall Street estimate of $0.21. Worldwide pump shipments … Full story available on Benzinga.com

Over the past 3 months, 4 analysts have published their opinion on Tandem Diabetes Care (NASDAQ:TNDM) stock. These analysts are typically employed by large Wall Street banks and tasked with understand

Over the past 3 months, 4 analysts have published their opinion on Tandem Diabetes Care (NASDAQ: TNDM ) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company''s business to predict how a stock will trade over the upcoming year. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 2 1 0 0 Last 30D 1 1 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 1 0 0 0 3M Ago 0 0 0 0 0 According to 4 analyst offering 12-month price targets in the last 3 months, Tandem Diabetes Care has an average price target of $150.25 with a high of $166.00 and a low of $120.00. Below is … Full story available on Benzinga.com

Robust domestic and international pump shipments are driving Tandem Diabetes' (TNDM) fourth-quarter top line.

Robust domestic and international pump shipments are driving Tandem Diabetes' (TNDM) fourth-quarter top line.

Tandem Diabetes Care, Inc. (TNDM) CEO John Sheridan on Q4 2021 Results - Earnings Call Transcript

Tandem Diabetes Care, Inc. (TNDM) delivered earnings and revenue surprises of -20% and 6.08%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the st

Shares of Tandem Diabetes Care (TNDM) are up in after-hours trading even though the company missed on the bottom line in its Q4 2021 earnings.

You should read the following discussion and analysis together with "Selected Financial Data" in Part II, Item 6 and our consolidated financial statements and related notes in Part II, Item 8. The following discussion contains forward-looking statements, which statements are subject to considerable risks and uncertainties. Future filings with the SEC, The post TANDEM DIABETES CARE INC 10-K Management''s Discussion and Analysis of Financial Condition and Results of Operations. appeared first on InsuranceNewsNet .

Tandem Diabetes Care press release (TNDM): Q4 GAAP EPS of $0.16 misses by $0.06.Revenue of $210M (+24.9% Y/Y) beats by $11.17M.

Tandem Diabetes Care, Inc. (TNDM) delivered earnings and revenue surprises of -20% and 6.08%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the st

Tandem Diabetes Care (NASDAQ:TNDM) is scheduled to announce Q4 earnings results on Tuesday, February 22nd, after market close.The consensus EPS Estimate is $0.21 and the consensus